TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Dendreon's Dip Creates a Great Opportunity VFC submits: Shares of Dendreon (DNDN) dropped to under thirty seven dollars on Monday morning, closing the day ten percent to the downside at $36.70. A dip in the DNDN share price had been expected by some during the time between the FDA's announcement of Provenge approval and the commercial launch of the product, but Monday's drop may also have been the result of an 'honest mistake' by CNBC who had reported that the supply of Provenge outweighed the current demand. CNBC corrected their mistake later in the day, stating that, in actuality, the demand for Provenge outweighed the supply. By then, however, the damage had been done and the DNDN stock embarked on a 10% downward spiral for the day.Speculation was rampant around the Internet and in the blogosphere that CNBC's 'mistake' was not quite an honest one, but one intended to help out some Wall Street buddies looking to build on their positions for lower prices. CNBC's already suspect track record of honest reporting - including Jim Cramer's questionable tactics - only add fuel to the fire. Complete Story » seekingalpha.com |
Abiomed, Inc. F1Q11 (Qtr End 06/30/10) Earnings Call Transcript Abiomed, Inc. (ABMD)F1Q11 (Qtr End 06/30/10) Earnings Call TranscriptAugust 4, 2010 8:00 am ETComplete Story » seekingalpha.com |
Enzo Biochem's Clinical Lab Takes Major Step in Becoming National Provider of Predictive Diagnostics (Business Wire) NEW YORK----In the first of several moves to expand the Company’s position as a national provider of esoteric and high value diagnostics, Enzo Biochem, Inc. announced today that its Enzo Clinical Labs division has been awarded a license for doing business in the Commonwealth of Pennsylvania, the first of several for which it has applied. us.rd.yahoo.com |
U.S. Delays Approval of Diabetes Treatment Eli Lilly and two smaller drug makers said late Tuesday that regulators have delayed approving a long-acting diabetes treatment in the final stages of development in order to further study a safety issue. online.wsj.com |
Near-Term Uncertainty Makes SIGA Technologies a Low-Risk Buy Above Average Odds Investing submits: The investment analysis below is our ninth in our ongoing series of guest write-ups, and is brought to you by a friend of the blog, Ryan Morris. Ryan is managing partner at Meson Capital, a focused, value oriented hedge fund based out of New York/Toronto (we would note that Ryan is also a Contributor at Sum Zero, a member of both VIC and DDIC, as well as the newest "value voice" at the fantastic CGI Value). Meson was formed in February 2009 and has returned north of 400% net to partners since its inception (for what it's worth, we actually had to rub our eyes a bit the first time we saw it. Incredible no?). Anyhow, we found Ryan's write-up on current AAOI Partners Fund holding SIGA Technologies (SIGA) to be not only cogent and concise, but particularly timely given the company's recent developments and the minimal reaction to what was undoubtedly a game changing event for the company and its future.Complete Story » seekingalpha.com |